NOT-AG-21-057: Notice to Extend the Expiration Date of PAR-18-877 "Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional)"

Notice to Extend the Expiration Date of PAR-18-877 "Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional)"

Notice Number:

NOT-AG-21-057

Key Dates

Release Date:

September 1, 2021

Related Announcements

PAR-18-877 - Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional)

Issued by

National Institute on Aging (NIA)

Purpose

This Notice informs potential applicants that the expiration date for Funding Opportunity Announcement (FOA) PAR-18-877 "Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional)" will be extended by one receipt cycle. The FOA now expires on January 8, 2022.

The following Section of PAR-18-877 has been modified:

Part 1. Overview Information

Key Dates

Currently Reads:

Expiration Date: September 8, 2021

Modified to Read (changes shown in bold italics):

Expiration Date: January 8, 2022

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Kristina McLinden, Ph.D.
National Institute on Aging (NIA)
Phone: 301-827-2563
Email: [email protected]